02197

三葉草生物－Ｂ

• PUBT·06/05 11:08

  Clover Biopharma tightens share-trading controls for grantors after Model Code breaches

• PUBT·06/01 20:12

  Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia

• PUBT·06/01 12:10

  Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors

• PUBT·04/21 14:01

  Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation

• Reuters·04/02 10:23

  Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million

• Reuters·03/29 22:08

  Clover completes enrollment in Australia Phase 2 trial for RSV combination vaccine candidates

• Reuters·03/27 12:27

  Clover Biopharmaceuticals grants 10.2 million options; RSUs climb to 9.0 million

• Reuters·03/25 22:13

  Clover Biopharmaceuticals FY2025 loss narrows 77.3% to RMB205 million; revenue drops 90.9% to RMB3.5 million

• Reuters·03/25 22:12

  CLOVER BIOPHARMACEUTICALS FY REVENUE RMB 3.5 MILLION

• Reuters·03/24 23:42

  Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial

• Reuters·03/24 23:42

  Clover reports Phase I data showing SCB-1019 RSV revaccination raises neutralizing antibody titers 60%-80% versus GSK’s Arexvy

• Reuters·03/22 11:58

  Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment

• Reuters·03/13 10:57

  Clover Biopharmaceuticals to hold board meeting to approve annual results and consider final dividend

• Reuters·01/12 04:27

  Clover Biopharmaceuticals Launches Phase 2 Trial for RSV-hMPV-PIV3 Combination Vaccine Candidates

• Simply Wall St·01/07 01:30

  Clover Biopharmaceuticals, Ltd.'s (HKG:2197) market cap rose HK$311m last week; retail investors who hold 53% profited and so did insiders